Skip to main content
main-content

Canagliflozin

News

12-06-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

15-04-2019 | Nephropathy | Highlight | News

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

17-03-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

Read more

Opinion

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

22-08-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials (11:17).

Journal articles and book chapters

05-09-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

23-07-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

23-06-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

Case reports

Image Credits